4-Oct-2024
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 4-Oct 4:05 PM ET)
Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm
Globe Newswire (Thu, 3-Oct 12:16 PM ET)
Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)
TipRanks (Tue, 1-Oct 6:36 AM ET)
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
Globe Newswire (Wed, 25-Sep 7:00 AM ET)
Globe Newswire (Fri, 20-Sep 5:00 AM ET)
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Globe Newswire (Thu, 29-Aug 7:00 AM ET)
PRNewswire (Thu, 8-Aug 7:29 AM ET)
Globe Newswire (Thu, 8-Aug 7:00 AM ET)
venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies
Business Wire (Thu, 1-Aug 8:00 AM ET)
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
Globe Newswire (Thu, 1-Aug 7:05 AM ET)
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Apellis Pharmaceuticals trades on the NASDAQ stock market under the symbol APLS.
As of October 4, 2024, APLS stock price declined to $27.51 with 1,391,404 million shares trading.
APLS has a beta of 0.23, meaning it tends to be less sensitive to market movements. APLS has a correlation of 0.00 to the broad based SPY ETF.
APLS has a market cap of $3.35 billion. This is considered a Mid Cap stock.
Last quarter Apellis Pharmaceuticals reported $200 million in Revenue and -$.28 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.04.
In the last 3 years, APLS traded as high as $94.75 and as low as $19.83.
The top ETF exchange traded funds that APLS belongs to (by Net Assets): VTI, VB, XBI, VXF, VBK.
APLS has underperformed the market in the last year with a price return of -26.9% while the SPY ETF gained +36.6%. APLS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.3% and -15.4%, respectively, while the SPY returned +4.2% and +0.8%, respectively.
APLS support price is $27.02 and resistance is $29.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APLS shares will trade within this expected range on the day.